1. deSouza RM, Moro E, Lang AE, et al. Timing of deep brain stimulation in Parkinson disease: a need for reappraisal? Ann Neurol 2013;73(5):565–75.
2. Kaňovský P, Kubová D, Bareš M, et al. L-DOPA induced dyskinesias and the continuous subcutaneous infusions of apomorphine – results of two years, prospective follow-up. Mov Disord 2002;17(1):188–91.
3. Růžička E, Streitová H, Jech R, et al. Amantadine-sulfate infusion in treatment of motor fluctuations and dyskinesias in Parkinson’s disease. J Neural Transm 2000;107(11):1297–306.
4. Nyholm D, Klangemo K, Johansson A. Levodopa/ carbidopa intestinal gel infusion long-term therapy in advanced Parkinson’s disease. Eur J Neurol 2012;19(8):1079–85.
5. Bareš M, Rektorová I, Jech R, et al. Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson’s disease? J Neural Transm 2012;119(3):373–80.
6. Li W, Chen S, Li J. Human induced pluripotent stem cells in Parkinson’s disease: a novel cell source of cell therapy and disease modeling. Progress Neurobiol 2015;134:161–77.
7. Ma Y, Peng S, Dhawan V, et al. Dopamine cell transplantation in Parkinson’s disease: challenge and perspective. Brit Med Bull 2011;100:173–89.
8. Morizane A, Doi D, Kikuchi T, et al. Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a nonhuman primate. Stem Cell Rep 2013;1:283–92.
9. Brandl B, Schneider SA, Loring JF, et al. Stem Cell Repro-gramming: Basic Implications and Future Perspective for Movement Disorders. Mov Disord 2015;30(3):301–12.